Financhill
Sell
16

IART Quote, Financials, Valuation and Earnings

Last price:
$12.15
Seasonality move :
0.41%
Day range:
$12.12 - $12.67
52-week range:
$11.60 - $32.66
Dividend yield:
0%
P/E ratio:
70.14x
P/S ratio:
0.57x
P/B ratio:
0.62x
Volume:
954.2K
Avg. volume:
1.5M
1-year change:
-55.93%
Market cap:
$945M
Revenue:
$1.6B
EPS (TTM):
-$0.38

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IART
Integra Lifesciences Holdings
$418.8M $0.58 -5.53% 241.78% $16.13
ISRG
Intuitive Surgical
$2.4B $1.96 16.8% 32.43% $575.49
LMAT
LeMaitre Vascular
$60.7M $0.54 11.88% 8.76% $104.50
OM
Outset Medical
$30.5M -$0.89 7.36% -90.13% $26.50
PODD
Insulet
$644.7M $1.10 25.31% -64.13% $334.74
TFX
Teleflex
$790.6M $3.37 2.91% 98.97% $155.92
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IART
Integra Lifesciences Holdings
$12.16 $16.13 $945M 70.14x $0.00 0% 0.57x
ISRG
Intuitive Surgical
$512.18 $575.49 $183.6B 75.10x $0.00 0% 21.34x
LMAT
LeMaitre Vascular
$81.13 $104.50 $1.8B 40.97x $0.20 0.89% 8.19x
OM
Outset Medical
$19.96 $26.50 $353.7M -- $0.00 0% 0.75x
PODD
Insulet
$304.63 $334.74 $21.4B 54.79x $0.00 0% 10.25x
TFX
Teleflex
$119.93 $155.92 $5.3B 37.83x $0.34 1.13% 1.86x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IART
Integra Lifesciences Holdings
54.74% 1.009 107.86% 0.57x
ISRG
Intuitive Surgical
-- 1.668 -- 3.81x
LMAT
LeMaitre Vascular
32.58% 1.475 8.86% 13.65x
OM
Outset Medical
35.65% 3.445 47.09% 6.60x
PODD
Insulet
56.03% 2.516 9.18% 3.24x
TFX
Teleflex
31.78% 0.357 30.89% 1.11x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IART
Integra Lifesciences Holdings
$194.4M -$15.5M -0.86% -1.88% -2.93% -$40.2M
ISRG
Intuitive Surgical
$1.5B $578.1M 15.82% 15.82% 25.66% $465M
LMAT
LeMaitre Vascular
$41.4M $12.6M 11.41% 13.74% 25.94% $7.7M
OM
Outset Medical
$11.1M -$16.4M -44.16% -140.06% -74.31% -$25.8M
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M
TFX
Teleflex
$389.4M $130.3M 2.43% 3.41% 18.2% $43.1M

Integra Lifesciences Holdings vs. Competitors

  • Which has Higher Returns IART or ISRG?

    Intuitive Surgical has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 30.99%. Integra Lifesciences Holdings's return on equity of -1.88% beat Intuitive Surgical's return on equity of 15.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
    ISRG
    Intuitive Surgical
    64.69% $1.92 $17.2B
  • What do Analysts Say About IART or ISRG?

    Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 32.61%. On the other hand Intuitive Surgical has an analysts' consensus of $575.49 which suggests that it could grow by 12.36%. Given that Integra Lifesciences Holdings has higher upside potential than Intuitive Surgical, analysts believe Integra Lifesciences Holdings is more attractive than Intuitive Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    IART
    Integra Lifesciences Holdings
    2 5 2
    ISRG
    Intuitive Surgical
    14 9 1
  • Is IART or ISRG More Risky?

    Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.396% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.875%.

  • Which is a Better Dividend Stock IART or ISRG?

    Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IART or ISRG?

    Integra Lifesciences Holdings quarterly revenues are $382.7M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Integra Lifesciences Holdings's net income of -$25.3M is lower than Intuitive Surgical's net income of $698.4M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Intuitive Surgical's PE ratio is 75.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 21.34x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IART
    Integra Lifesciences Holdings
    0.57x 70.14x $382.7M -$25.3M
    ISRG
    Intuitive Surgical
    21.34x 75.10x $2.3B $698.4M
  • Which has Higher Returns IART or LMAT?

    LeMaitre Vascular has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 18.39%. Integra Lifesciences Holdings's return on equity of -1.88% beat LeMaitre Vascular's return on equity of 13.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
    LMAT
    LeMaitre Vascular
    69.18% $0.48 $515.6M
  • What do Analysts Say About IART or LMAT?

    Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 32.61%. On the other hand LeMaitre Vascular has an analysts' consensus of $104.50 which suggests that it could grow by 28.81%. Given that Integra Lifesciences Holdings has higher upside potential than LeMaitre Vascular, analysts believe Integra Lifesciences Holdings is more attractive than LeMaitre Vascular.

    Company Buy Ratings Hold Ratings Sell Ratings
    IART
    Integra Lifesciences Holdings
    2 5 2
    LMAT
    LeMaitre Vascular
    3 6 0
  • Is IART or LMAT More Risky?

    Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.396% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.35%.

  • Which is a Better Dividend Stock IART or LMAT?

    Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.89% to investors and pays a quarterly dividend of $0.20 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios IART or LMAT?

    Integra Lifesciences Holdings quarterly revenues are $382.7M, which are larger than LeMaitre Vascular quarterly revenues of $59.9M. Integra Lifesciences Holdings's net income of -$25.3M is lower than LeMaitre Vascular's net income of $11M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while LeMaitre Vascular's PE ratio is 40.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 8.19x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IART
    Integra Lifesciences Holdings
    0.57x 70.14x $382.7M -$25.3M
    LMAT
    LeMaitre Vascular
    8.19x 40.97x $59.9M $11M
  • Which has Higher Returns IART or OM?

    Outset Medical has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of -86.66%. Integra Lifesciences Holdings's return on equity of -1.88% beat Outset Medical's return on equity of -140.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
    OM
    Outset Medical
    37.19% -$3.66 $264M
  • What do Analysts Say About IART or OM?

    Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 32.61%. On the other hand Outset Medical has an analysts' consensus of $26.50 which suggests that it could grow by 32.77%. Given that Outset Medical has higher upside potential than Integra Lifesciences Holdings, analysts believe Outset Medical is more attractive than Integra Lifesciences Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    IART
    Integra Lifesciences Holdings
    2 5 2
    OM
    Outset Medical
    3 2 0
  • Is IART or OM More Risky?

    Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.396% more volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IART or OM?

    Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IART or OM?

    Integra Lifesciences Holdings quarterly revenues are $382.7M, which are larger than Outset Medical quarterly revenues of $29.8M. Integra Lifesciences Holdings's net income of -$25.3M is higher than Outset Medical's net income of -$25.8M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 0.75x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IART
    Integra Lifesciences Holdings
    0.57x 70.14x $382.7M -$25.3M
    OM
    Outset Medical
    0.75x -- $29.8M -$25.8M
  • Which has Higher Returns IART or PODD?

    Insulet has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 6.22%. Integra Lifesciences Holdings's return on equity of -1.88% beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About IART or PODD?

    Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 32.61%. On the other hand Insulet has an analysts' consensus of $334.74 which suggests that it could grow by 9.89%. Given that Integra Lifesciences Holdings has higher upside potential than Insulet, analysts believe Integra Lifesciences Holdings is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    IART
    Integra Lifesciences Holdings
    2 5 2
    PODD
    Insulet
    14 2 0
  • Is IART or PODD More Risky?

    Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.396% more volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

  • Which is a Better Dividend Stock IART or PODD?

    Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IART or PODD?

    Integra Lifesciences Holdings quarterly revenues are $382.7M, which are smaller than Insulet quarterly revenues of $569M. Integra Lifesciences Holdings's net income of -$25.3M is lower than Insulet's net income of $35.4M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Insulet's PE ratio is 54.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 10.25x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IART
    Integra Lifesciences Holdings
    0.57x 70.14x $382.7M -$25.3M
    PODD
    Insulet
    10.25x 54.79x $569M $35.4M
  • Which has Higher Returns IART or TFX?

    Teleflex has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 13.56%. Integra Lifesciences Holdings's return on equity of -1.88% beat Teleflex's return on equity of 3.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
    TFX
    Teleflex
    55.58% $2.07 $6B
  • What do Analysts Say About IART or TFX?

    Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 32.61%. On the other hand Teleflex has an analysts' consensus of $155.92 which suggests that it could grow by 30.01%. Given that Integra Lifesciences Holdings has higher upside potential than Teleflex, analysts believe Integra Lifesciences Holdings is more attractive than Teleflex.

    Company Buy Ratings Hold Ratings Sell Ratings
    IART
    Integra Lifesciences Holdings
    2 5 2
    TFX
    Teleflex
    0 11 0
  • Is IART or TFX More Risky?

    Integra Lifesciences Holdings has a beta of 1.164, which suggesting that the stock is 16.396% more volatile than S&P 500. In comparison Teleflex has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.761%.

  • Which is a Better Dividend Stock IART or TFX?

    Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 1.13% to investors and pays a quarterly dividend of $0.34 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios IART or TFX?

    Integra Lifesciences Holdings quarterly revenues are $382.7M, which are smaller than Teleflex quarterly revenues of $700.7M. Integra Lifesciences Holdings's net income of -$25.3M is lower than Teleflex's net income of $95M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Teleflex's PE ratio is 37.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.57x versus 1.86x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IART
    Integra Lifesciences Holdings
    0.57x 70.14x $382.7M -$25.3M
    TFX
    Teleflex
    1.86x 37.83x $700.7M $95M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Is TTD The Big Winner If Pharma Ads Are Banned?
Is TTD The Big Winner If Pharma Ads Are Banned?

Last week, Senators Bernie Sanders and Angus King introduced a…

Is Palantir Stock Overvalued?
Is Palantir Stock Overvalued?

By every traditional yardstick, including a price‑to‑sales well above 100,…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
11
VEON alert for Jun 14

VEON [VEON] is down 18.57% over the past day.

Buy
74
DAVE alert for Jun 14

Dave [DAVE] is down 12.68% over the past day.

Buy
54
DAR alert for Jun 14

Darling Ingredients [DAR] is up 9.12% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock